THANK YOU FOR SUBSCRIBING
As part of the Series B round, ElevateBio also announced that Germano Giuliani will join ElevateBio's Board of Directors, as part of the deal. Giuliani is an industry expert and a member of the Board of Directors at HBM Healthcare Investments AG
Fremont, CA: Innovative cell and gene therapy company portfolio creator ElevateBio, LLC secured USD 170 million in a Series B funding round participated by The Invus Group, Surveyor Capital (A Citadel company), EDBI, and Vertex Ventures. Existing investors F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, and Samsara BioCapital also participated in the financing round. The Cambridge based company will use the newly raised capital to support and accelerate the company's next phase of growth.
"In less than a year since launching ElevateBio, we have firmly established our first-of-its-kind business model in cell and gene therapy, by announcing our initial two therapeutic companies, commencing operations for additional companies, and entering into a 10-year manufacturing partnership with one of the world's top hospital systems," said David Hallal, Co-Founder and Chief Executive Officer of ElevateBio. "With the support of our new and existing investors, our highly disruptive, capitally efficient model uniquely positions ElevateBio to accelerate the rate of innovation in cell and gene therapy manufacturing, enabling technology platforms, and therapeutic development for many years to come."
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Check Out: Elevate Semiconductor
As part of the Series B round, ElevateBio also announced that Germano Giuliani will join ElevateBio's Board of Directors. Giuliani is an industry expert and a member of the Board of Directors at HBM Healthcare Investments AG, a position he has held since 2012. "We are thrilled to welcome Germano to the ElevateBio Board," said Mr. Hallal. "Germano's deep pharmaceutical executive experience building long-term value for all stakeholders as an operator, Board member, and the investor will play a significant role at ElevateBio as we advance the development of life-transforming therapies to serve patients around the world."
The new funding will allow the company's BaseCamp to be fully operational with cGMP manufacturing. The funds will also be used towards the advancement of clinical development with at least six-cell and gene therapies from across its portfolio companies to enter clinical studies this year and into 2021. Cell and gene therapies are recognized as the future of precision medicine globally, and we believe ElevateBio's platform enables product innovation to be accelerated with their unique business model and manufacturing expertise," said Chu Swee Yeok, Chief Executive Officer and President of EDBI. "As ElevateBio continues to expand their global footprint, they are ideally suited to partner with biotech companies and academic centers in Asia to discover and develop novel therapies to treat cancers and rare diseases."
See also: Top Healthcare Solution Companies
More in News